NORWICH, UK – 07 January 2021: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation based in Norwich, UK, has announced today that it has produced three further products to support research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic.
The products developed include:
News
AMSBIO has introduced a series of kit products based upon high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
These new kit products include SARS-CoV-2 inhibitor screening kits, antibody titer serologic assay kits, antigen detection kit and antigen pre-coated plates.
Cambridge 04 January 2021: Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is pleased to welcome three new members to its board.
Stevenage, UK – 31 December 2020
Dr Sally Ann Forsyth, CEO of Stevenage Bioscience Catalyst (SBC), thanks her colleagues and collaborators after being honoured in the 2021 New Year Honours list. Sally Ann has been awarded an Officer of the Order of the British Empire (OBE) for services to business and science.
Issue 12 / December 2020
Latest legal newsletter from Mills & Reeve - Regulatory framework for medicines and medical devices as we reach the end of the transition period for leaving the EU, AI and healthtech and more, including recordings from Genesis 2020 (Taking a UK Private company to Nasdaq) and the latest Legal Forum.
https://update.mills-reeve.com/12/2613/december-2020/life-sciences---seq...
Tokyo, Japan and Cambridge, UK, 22 December 2020 – Sosei Group Corporation (“the Company”; TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA (“Captor”; Wroclaw, Poland and Allschwil, Switzerland), a European leader in targeted protein degradation, have entered a strategic technology collaboration focused on the discovery and development of novel small molecules that target the degradation of disease-associated G protein-coupled receptors (GPCRs).
As we look towards 2021 and beyond, Deloitte has unveiled ten predictions on how patients, healthcare and life science companies and their staff might behave and operate in five years’ time, based on today’s evidence.
• Advances in AI-enabled robotics, cognitive automation, digitalisation and life-long learning will help task shifting and role-enrichment, changing the who, what, and where of work.
Research Triangle Park, NC, USA and Cambridge, UK, 18 December 2020 – Inivata, a leader in liquid biopsy, today announces its participation in a major research collaboration to investigate integrated diagnostics for the early detection of lung cancer with the aim of increasing survival rates, alongside improving the efficiency of testing in people at high risk of cancer in the NHS. The program’s goal is to streamline the process of detecting cancers and reduce the NHS resources that are needed in order to find each new case.
Cambridge, UK, 17 December 2020 Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (MOGRIFY® V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (MOGRIFY V2).